CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 12 enrolled
Drug / intervention
UX003drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02432144
NCT02432144Phase 3Completed
CompareCT.gov

A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects With MPS 7

Ultragenyx Pharmaceutical Inc·interventional·Posted May 1, 2015·Updated Jul 30, 2020

In Brief

A Phase 3 clinical trial evaluating UX003 for Sly Syndrome and 3 related conditions. Completed, enrolled 12 participants across 7 sites in 4 countries.

Detailed Summary

The primary objective of the study is to evaluate the long-term safety of UX003 in subjects with MPS 7.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSly Syndrome, MPS VII, Mucopolysaccharidosis, Mucopolysaccharidosis VII
CountriesBrazil, Mexico, Portugal, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 1, 2015
Enrollment StartNov 10, 2015
Primary CompletionJan 14, 2019
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 11.2 years ago

Interventions

UX003drug

solution for intravenous (IV) infusion